Connor, Clark & Lunn Investment Management (CC&L)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,263	Closed	-$44.7K	–	1499
2022 Q4	$44.7K	Sell	1,263 -359	-22%	-$43.1K	﹤0.01%	1153
2022 Q3	$366K	Buy	1,622 +1,143	+239%	+$281K	﹤0.01%	877
2022 Q2	$91K	Sell	479 -293	-38%	-$59.1K	﹤0.01%	985
2022 Q1	$192K	Buy	+772	New	+$122K	﹤0.01%	948
2020 Q4	–	Sell	-417	Closed	-$102K	–	1072
2020 Q3	$102K	Sell	417 -2,176	-84%	-$677K	﹤0.01%	873
2020 Q2	$747K	Sell	2,593 -189	-7%	-$55.7K	0.01%	675
2020 Q1	$567K	Buy	2,782 +2,303	+481%	+$734K	0.01%	664
2019 Q4	$214K	Buy	+479	New	+$170K	﹤0.01%	826
2016 Q1	–	Sell	-46	Closed	-$30K	–	914
2015 Q4	$30K	Hold	46	–	–	﹤0.01%	799
2015 Q3	$22K	Buy	+46	New	+$24.4K	﹤0.01%	702
2015 Q2	–	Sell	-79	Closed	-$676K	–	675
2015 Q1	$676K	Buy	79 +55	+229%	+$481K	0.01%	359
2014 Q4	$213K	Buy	+24	New	+$139K	﹤0.01%	518

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EIGR Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2023, closing a stake of 1,263 shares — an estimated $44.7K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EIGR in Q4 2014 and held it in 12 quarters. The position peaked at $747K in Q2 2020. 71 funds tracked by Wall St. Rank hold EIGR as of Q1 2023.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 1,263 Eiger BioPharmaceuticals, Inc. shares in Q1 2023, an estimated $44.7K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 12 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Eiger BioPharmaceuticals, Inc. position peaked at $747K in Q2 2020.
71 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.